Unicorn Biotechnologies
Automated biomanufacturing platform for cell-based product scaling.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $3.2m | Seed | |
| Total Funding | 000k | ||
Related Content
Unicorn Biotechnologies is a biotechnology firm developing a biomanufacturing platform to automate cell production. The company was founded in 2020 by Jack Reid (CEO) and Dr. Adam Glen (CTO) and is headquartered in Sheffield, UK. The founders met during an entrepreneurship program and began the company in an attic before moving into a dedicated lab space.
Co-founder Jack Reid has a background in chemistry and philosophy from Bates College and the University of Cambridge, and was a Fulbright Fellow. Dr. Adam Glen has over two decades of experience in stem cell culture, protein biochemistry, and automating manufacturing processes for mammalian cells. The company was established to address the manufacturing bottlenecks that hinder the mass-market scalability of cell-based products, such as cultivated meat and cell therapies.
Unicorn Biotechnologies provides automated, modular systems designed to make the development and manufacturing of cell-based products more efficient, affordable, and reliable. Their platform aims to reduce labor costs, minimize variability, and shorten production timelines. The company's flagship product, Emmet, is a bench-top machine that automates tissue culture flask workflows, integrating hardware and software to handle sensitive cell lines like pluripotent stem cells. The firm's business model focuses on providing this technology to cell manufacturers in markets such as cultivated meat, cell and gene therapy, and pharmaceuticals. Revenue is generated by offering their platform and technology to these clients.
Unicorn Biotechnologies has secured $3.2 million in total funding over three seed rounds. Its latest round in April 2022 was led by Acequia Capital and included investors such as HAX, SOSV, and Climate Capital.
Keywords: biomanufacturing, cell culture automation, cellular agriculture, cultivated meat, bioreactors, cell therapy manufacturing, automated bioprocessing, stem cell manufacturing, bioprocess scaling, lab automation, tissue engineering, regenerative medicine, automated cell culture, bioproduction, smart machines, industrial biotechnology, cell-based products, bioprocess development, advanced therapies, life sciences hardware, mammalian cell culture